AR113835A1 - Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía - Google Patents

Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía

Info

Publication number
AR113835A1
AR113835A1 ARP180103232A ARP180103232A AR113835A1 AR 113835 A1 AR113835 A1 AR 113835A1 AR P180103232 A ARP180103232 A AR P180103232A AR P180103232 A ARP180103232 A AR P180103232A AR 113835 A1 AR113835 A1 AR 113835A1
Authority
AR
Argentina
Prior art keywords
glp
small intestine
during
peptibodies
analogues
Prior art date
Application number
ARP180103232A
Other languages
English (en)
Spanish (es)
Original Assignee
Shire Nps Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Nps Pharmaceuticals Inc filed Critical Shire Nps Pharmaceuticals Inc
Publication of AR113835A1 publication Critical patent/AR113835A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP180103232A 2017-11-06 2018-11-06 Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía AR113835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
AR113835A1 true AR113835A1 (es) 2020-06-17

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103232A AR113835A1 (es) 2017-11-06 2018-11-06 Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía

Country Status (14)

Country Link
US (1) US11660328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102825098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629745A (cg-RX-API-DMAC7.html)
AR (1) AR113835A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018360744A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079523A1 (cg-RX-API-DMAC7.html)
IL (1) IL274098B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004620A (cg-RX-API-DMAC7.html)
TW (1) TWI911137B (cg-RX-API-DMAC7.html)
WO (1) WO2019090209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002080B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
IL274098B1 (en) 2024-08-01
US20210169986A1 (en) 2021-06-10
EP3706774A4 (en) 2021-09-08
TW201922279A (zh) 2019-06-16
KR20200085763A (ko) 2020-07-15
MX2020004620A (es) 2020-10-12
JP7296958B2 (ja) 2023-06-23
CA3079523A1 (en) 2019-05-09
TWI911137B (zh) 2026-01-11
RU2020118172A (ru) 2021-12-08
KR102825098B1 (ko) 2025-06-26
AU2018360744A1 (en) 2020-05-07
JP7752152B2 (ja) 2025-10-09
CN111629745A (zh) 2020-09-04
IL274098B2 (en) 2024-12-01
JP2023107883A (ja) 2023-08-03
US11660328B2 (en) 2023-05-30
ZA202002080B (en) 2025-11-26
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
BR112020008936A2 (pt) 2020-10-20
IL274098A (en) 2020-06-30
EP3706774A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
MX2020004620A (es) Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2016015466A (es) Metodo para tratar dializado, sistema de dialisis y metodo para pre-evaluar pacientes de dialisis para el tratamiento con los mismos.
JP2016519078A5 (cg-RX-API-DMAC7.html)
BR112015021446A2 (pt) métodos cirúrgicos empregando composições de peptídeo amfifílico purificado
AR103246A1 (es) Derivados de fgf21 y sus usos
AR045906A1 (es) Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
EA201791333A1 (ru) Производные глюкагона с улучшенной стабильностью
AR106364A1 (es) Derivados de insulina y sus usos médicos
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX390945B (es) Compuestos para el tratamiento de tnbc.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EP3773530A4 (en) RAPID IMPROVEMENT OF VASCULAR DISEASES BY ADMINISTRATION OF VITAMIN K
CL2020000310A1 (es) Análogos de insulina acilados novedosos y usos de estos.
ES2686114T3 (es) El ácido hialurónico y su uso para el tratamiento de la insuficiencia venosa y las venas varicosas
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
CO2018000768A2 (es) Administración intravenosa de citrulina durante la cirugía
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
EA201591910A1 (ru) Стабильный раствор бромфенака
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
PE20191462A1 (es) Composicion liquida que contiene pradofloxacina
BR112017006200A2 (pt) dispositivos de fio de fita transósseo e um sistema e método para utilizar os dispositivos